Developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need

About Spruce Bio

Spruce is committed to transforming the lives of patients living with neurological and endocrine disorders by developing and commercializing novel therapies where there is significant unmet medical need.

Learn More

A Novel Approach Tildacerfont

Tildacerfont is actively being studied as an innovative non-steroidal approach to treating polycystic ovary syndrome (PCOS), major depressive disorder (MDD), and other disorders.

Tildacerfont is a potent and highly selective, non-steroidal, oral antagonist of the CRF₁ receptor, which is the receptor for corticotropin-releasing factor (CRF), a hormone that is secreted by the hypothalamus.

CRF₁ receptors play a significant role in the body’s response to stress and are implicated in various conditions, including MDD.

By blocking the CRF₁ receptor, tildacerfont has the potential to address hyperactive brain CRF neurotransmission and aberrant functioning of the hypothalamic–pituitary-adrenal (HPA) axis in patients with MDD.

Learn More

Developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need

About Spruce Bio

News

December 10, 2024

Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH

November 11, 2024

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

October 28, 2024

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference